The story of Viagra, and its parent company copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in revenue , its intellectual property lapse created a wave of lower-priced alternatives , significantly eroding its market share . While some firms may attempt to capitalize on similar conditions , the